These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2532073)

  • 21. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.
    Ho AD; Lipp T; Ehninger G; Illiger HJ; Meyer P; Freund M; Hunstein W
    J Clin Oncol; 1988 Feb; 6(2):213-7. PubMed ID: 3422260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia.
    Thomas X; Cambier N; Taksin AL; Reman O; Vekhoff A; Pautas C; Leblond V; Soler-Michel P; Ecstein-Fraïssé E; Archimbaud E
    Leuk Res; 2000 Nov; 24(11):957-63. PubMed ID: 11086179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol.
    Slapak CA; Desforges JF; Fogaren T; Miller KB
    Am J Hematol; 1992 Nov; 41(3):178-83. PubMed ID: 1415192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group.
    De Witte T; Suciu S; Selleslag D; Labar B; Roozendaal K; Zittoun R; Ribeiro M; Kurstjens R; Hayat M; Dardenne M; Solbu G; Muus P
    Ann Hematol; 1996 Mar; 72(3):119-24. PubMed ID: 8766252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
    Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II clinical trial of carboplatin in relapsed and refractory leukemia.
    Vogler WR; Harrington DP; Winton EF; Lazarus HM; Bennett JM; Cassileth PA; Oken MM
    Leukemia; 1992 Oct; 6(10):1072-5. PubMed ID: 1405761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-azacytidine in acute leukemia.
    Saiki JH; McCredie KB; Vietti TJ; Hewlett JS; Morrison FS; Costanzi JJ; Stuckey WJ; Whitecar J; Hoogstraten B
    Cancer; 1978 Nov; 42(5):2111-4. PubMed ID: 82472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
    Vokes EE; Panje WR; Schilsky RL; Mick R; Awan AM; Moran WJ; Goldman MD; Tybor AG; Weichselbaum RR
    J Clin Oncol; 1989 Jun; 7(6):761-8. PubMed ID: 2715806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of terminal-phase chronic myelogenous leukemia with intermediate-dose cytarabine and hydroxyurea.
    Lazzarino M; Morra E; Brusamolino E; Alessandrino EP; Orlandi E; Pagnucco G; Castagnola C; Bernasconi P; Merante S; Bonfichi M
    Hematol Oncol; 1991; 9(6):299-305. PubMed ID: 1748396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chronic myelogenous leukemia with long-term hypoplasia induced by alpha-interferon and hydroxyurea].
    Motomura S; Sakai R; Tomita N; Fujimaki K; Hattori M; Fujisawa S; Mohri H; Takahashi N; Maruta A; Kodama F; Okubo T
    Rinsho Ketsueki; 1998 Apr; 39(4):302-7. PubMed ID: 9597898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study.
    Bennett JM; Lymann GH; Cassileth PA; Glick JH; Oken MM
    Am J Clin Oncol; 1984 Oct; 7(5):471-3. PubMed ID: 6594926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea.
    Trümper LH; Ho AD; Hunstein W; van der Lelie H; Goudsmit R
    Blut; 1989 Feb; 58(2):85-7. PubMed ID: 2522015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
    Kantarjian HM; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang LY; Rios MB; Keating MJ; Meyer M
    Leukemia; 1996 Mar; 10(3):396-401. PubMed ID: 8642853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia.
    Wiernik PH; Glidewell OJ; Hoagland HC; Brunner KW; Spurr CL; Cuttner J; Silver RT; Carey RW; DelDuca V; Kung FH; Holland JF
    Med Pediatr Oncol; 1979; 6(3):261-77. PubMed ID: 381887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia.
    Mamez AC; Raffoux E; Chevret S; Lemiale V; Boissel N; Canet E; Schlemmer B; Dombret H; Azoulay E; Lengliné E
    Leuk Lymphoma; 2016 Oct; 57(10):2281-8. PubMed ID: 26849624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial.
    Nand S; Godwin J; Smith S; Barton K; Michaelis L; Alkan S; Veerappan R; Rychlik K; Germano E; Stiff P
    Leuk Lymphoma; 2008 Nov; 49(11):2141-7. PubMed ID: 19021057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Continuous infusion diaziquone and etoposide: a phase I study in adult patients with acute leukemia.
    Lee EJ; Reck K; Schiffer CA
    Leukemia; 1990 Mar; 4(3):189-92. PubMed ID: 2314118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.